Bevirimat Uses, Dosage, Side Effects and more

Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid. This compound belongs to the androgens and derivatives, which are hydroxylated C19 steroid hormones. They are known to favour the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. Bevirimat targets the protein gag-pol polyprotein. Bevirimat is derived from a betulinic acid-like compound, first isolated from Syzygium claviflorum, a Chinese herb. It is not currently FDA-approved, but is undergoing clinical trials conducted by the pharmaceutical company Panacos.

Trade Name Bevirimat
Generic Bevirimat
Bevirimat Other Names Bevirimat
Type
Formula C36H56O6
Weight Average: 584.8262
Monoisotopic: 584.407689524
Groups Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am

Uses

Investigated for use/treatment in HIV infection.

How Bevirimat works

Bevirimat has a novel mechanism of action, specifically inhibiting cleavage of spacer peptide 1 (SP1) from the C-terminus of capsid which results in defective core condensation. Specifically, bevirimat binds at the SP1/capsid junction, preventing cleavage by HIV protease.

Half Life

56.3 to 69.5 hours

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.
Share